Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $30.00

Key Points

• Avalo Therapeutics, Inc. has received a consensus rating of "Buy" from six research firms, with an average price target of $30.00.
• The company reported an earnings loss of ($1.25) per share, which was below the consensus estimate of ($1.07).
• Institutional investors hold 87.06% of Avalo Therapeutics' stock, indicating significant institutional interest in the company.

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) have received a consensus rating of "Buy" from the six ratings firms that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $30.00.

Separately, HC Wainwright upgraded shares of Avalo Therapeutics from a "hold" rating to a "buy" rating and set a $15.00 price target on the stock in a research note on Monday, June 2nd.

Avalo Therapeutics Stock Performance

Shares of AVTX traded up $1.06 during trading hours on Monday, hitting $7.72. 632,651 shares of the company were exchanged, compared to its average volume of 86,324. The firm's 50 day moving average is $4.95 and its 200-day moving average is $5.92. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.18). As a group, equities research analysts forecast that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC bought a new stake in Avalo Therapeutics during the 1st quarter worth about $7,209,000. Affinity Asset Advisors LLC increased its position in shares of Avalo Therapeutics by 1,123.9% in the fourth quarter. Affinity Asset Advisors LLC now owns 550,765 shares of the company's stock valued at $4,092,000 after acquiring an additional 505,765 shares during the last quarter. RWA Wealth Partners LLC acquired a new stake in shares of Avalo Therapeutics in the 1st quarter valued at approximately $2,505,000. Velan Capital Investment Management LP bought a new stake in shares of Avalo Therapeutics in the 4th quarter valued at about $817,000. Finally, Geode Capital Management LLC grew its position in shares of Avalo Therapeutics by 937.0% in the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company's stock valued at $779,000 after purchasing an additional 94,742 shares during the last quarter. 87.06% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.